US006680068B2

(12) **United States Patent**
Campbell et al.

(10) **Patent No.: US 6,680,068 B2**
(45) **Date of Patent: Jan. 20, 2004**

(54) **DRUG DELIVERY FORMULATIONS AND TARGETING**

(75) Inventors: **Robert B. Campbell**, Boston, MA (US); **Rakesh K. Jain**, Boston, MA (US)

(73) Assignee: **The General Hospital Corporation**, Boston, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/898,107**

(22) Filed: **Jul. 3, 2001**

(65) **Prior Publication Data**

US 2002/0090392 A1 Jul. 11, 2002

Related U.S. Application Data

(60) Provisional application No. 60/216,173, filed on Jul. 1, 2000.

(51) **Int. Cl.**[7] **A61K 9/127**; A61K 48/00

(52) **U.S. Cl.** **424/450**; 514/1; 514/2; 514/44

(58) **Field of Search** 424/450; 514/1, 514/2, 44

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,804,539 A	2/1989	Guo et al.	424/450
4,839,175 A	6/1989	Guo et al.	424/450

OTHER PUBLICATIONS

Verma et al (Nature 389: 239–242, 1997).*
Somia and Verma (Nature Reviews Genetics 1: 91–99, 2000).*
Anderson (Nature 392:25–30, 1998).*
Romano et al (Stem Cells 18: 19–39, 2000).*
McCluskie et al (Molecular Medicine 5 (5): 287–300, 1999).*
Chattergoon et al (FASEB J. 11: 753–763, 1997).*
Irvine et al (J. Immunol. 156(1): 238–245, 1996).*
Baldwin et al., (1991) Microvascular Research 42:160–178.
Dellian et al., (2000) British Journal of Cancer 82:1513–1518.
Folkman, (1990) Journal of the National Cancer Institute 82(1):4–6.
Hobbs et al., (1998)Proc. Natl. Acad. Sci. USA 95:4607–4612.
Jain, (1998) Nature Medicine 6:655–657.
Jain, (1994) Scientific American 271 (1):58–65.
Roberts et al., (1997) Cancer Research 57:765–772.
Thurston et al., (1998) Journal of Clinical Investigation 101:1401–1413.

* cited by examiner

Primary Examiner—Dave T. Nguyen
Assistant Examiner—Richard Schnizer
(74) *Attorney, Agent, or Firm*—Fish & Richardson P.C.

(57) **ABSTRACT**

The invention is based on the discovery that angiogenic vessels have heterogeneous surface charge and that cationic liposomes actually target human tumor blood vessels only in irregularly shaped patches. The invention thus features methods for delivering therapeutic compounds to angiogenic vascular endothelial surfaces using a mixture, or "cocktail", of positively charged and neutral liposomes. The new methods can be used to target multiple regions on the same tumor vessel and/or clusters of vessels within the same tumor. Liposomes with different chemical and/or physical properties (e.g., charge, stability, solubility, diameter) can be delivered simultaneously, and can target tumor vessels and other angiogenic vessels with greater efficiency compared to cationic liposomes alone.

14 Claims, No Drawings